Uterotonic Agents: Research Article

Felis S

doi:10.58372/2835-6276.1123

Authors

Felis S

DOI:

https://doi.org/10.58372/2835-6276.1123

Keywords:

Carboprost, Methylergonovine, Misoprostol, Oxytocin, Postpartum hemorrhage, Uterine atony, Uterotonic agent

Abstract

Uterine atony is a common cause of primary postpartum hemorrhage, which remains a major cause of pregnancy-related mortality for women worldwide. Oxytocin, methylergonovine, carboprost, and misoprostol are commonly used to restore uterine tone. Oxytocin is the first-line agent. Methylergonovine and carboprost are both highly effective second-line agents with severe potential side effects. Recent studies have called into question the effectiveness of misoprostol as an adjunct to other uterotonic agents, but it remains a useful therapeutic in resource-limited practice environments. We review the current role these medications play in the prevention and treatment of uterine atony.

References

Vannuccini S, Bocchi C, Severi FM, Challis JR, Petraglia F. Endocrinology of human parturition. Ann Endocrinol (Paris). 2016;77(2):105-13.

Drew T, Balki M. What does basic science tell us about the use of uterotonics? Best Practice & Research Clinical Obstetrics & Gynaecology. Vol 61, Nov 2019, Pages 3-14.

Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol. 2014;26(6):356-69.

Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629-83.

de Groot AN, van Dongen PW, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56(4):523-35.

O'Brien WF. The role of prostaglandins in labor and delivery. Clin Perinatol. 1995;22(4):973-84.

Fuchs AR, Romero R, Keefe D, Parra M, Oyarzun E, Behnke E. Oxytocin secretion and human parturition: pulse frequency and duration increase during spontaneous labor in women. Am J Obstet Gynecol. 1991;165(5 Pt 1):1515-23.

Devost D, Wrzal P, Zingg HH. Oxytocin receptor signalling. Prog Brain Res. 2008;170:167-76.

Prevention and Management of Postpartum Haemorrhage: Green-top Guideline No. 52. BJOG. 2017;124(5):e106-e49.

WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2018.

Committee on Practice B-O. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017;130(4):e168-e86.

Burger K, Fahrenholz F, Gimpl G. Non-genomic effects of progesterone on the signaling function of G protein-coupled receptors. FEBS Lett. 1999;464(1-2):25-9.

Qian XD, Beck WT. Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts. J Biol Chem. 1990;265(31):18753-6.

Gonser M. Labor induction and augmentation with oxytocin: pharmacokinetic considerations. Arch Gynecol Obstet. 1995;256(2):63-6.

Rousseau A, Burguet A. Oxytocin administration during spontaneous labor: Guidelines for clinical practice. Chapter 5: Maternal risk and adverse effects of using oxytocin augmentation during spontaneous labor. J Gynecol Obstet Hum Reprod. 2017;46(6):509-21.

Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesth. 2007;98(1):116-9.

Smith MP, Ayad VJ, Mundell SJ, McArdle CA, Kelly E, Lopez Bernal A. Internalization and desensitization of the oxytocin receptor is inhibited by Dynamin and clathrin mutants in human embryonic kidney 293 cells. Mol Endocrinol. 2006;20(2):379-88.

Phaneuf S, Rodriguez Linares B, TambyRaja RL, MacKenzie IZ, Lopez Bernal A. Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. J Reprod Fertil. 2000;120(1):91-7.

Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol. 2003;188(2):497-502.

Balki M, Erik-Soussi M, Kingdom J, Carvalho JC. Oxytocin pretreatment attenuates oxytocin-induced contractions in human myometrium in vitro. Anesthesiology. 2013;119(3):552-61.

Balki M, Ramachandran N, Lee S, Talati C. The Recovery Time of Myometrial Responsiveness After Oxytocin-Induced Desensitization in Human Myometrium In Vitro. Anesth Analg. 2016;122(5):1508-15.

Balki M, Ronayne M, Davies S, Fallah S, Kingdom J, Windrim R, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol. 2006;107(1):45-50.

Carvalho JC, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol. 2004;104(5 Pt 1):1005-10.

Belghiti J, Kayem G, Dupont C, Rudigoz RC, Bouvier-Colle MH, Deneux-Tharaux C. Oxytocin during labour and risk of severe postpartum haemorrhage: a population-based, cohort-nested case-control study. BMJ Open. 2011;1(2):e000514.

Budden A, Chen LJ, Henry A. High-dose versus low-dose oxytocin infusion regimens for induction of labour at term. Cochrane Database Syst Rev. 2014(10):CD009701.

Tran G, Kanczuk M, Balki M. The association between the time from oxytocin cessation during labour to Cesarean delivery and postpartum blood loss: a retrospective cohort study. Can J Anaesth. 2017;64(8):820-7.

Westhoff G, Cotter AM, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. 2013(10):CD001808.

Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther. 1992;52(1):60-7.

Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):15-20.

Atke A, Vilhardt H. Uterotonic activity and myometrial receptor affinity of 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin. Acta Endocrinol (Copenh). 1987;115(1):155-60.

Khan M, Balki M, Ahmed I, Farine D, Seaward G, Carvalho JC. Carbetocin at elective Cesarean delivery: a sequential allocation trial to determine the minimum effective dose. Can J Anaesth. 2014;61(3):242-8.

Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012(2):CD005457.

Boucher M, Horbay GL, Griffin P, Deschamps Y, Desjardins C, Schulz M, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol. 1998;18(3):202-7.

Widmer M, Piaggio G, Nguyen TMH, Osoti A, Owa OO, Misra S, et al. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. N Engl J Med. 2018;379(8):743-52.

Cole NM, Carvalho JC, Erik-Soussi M, Ramachandran N, Balki M. In Vitro Comparative Effect of Carbetocin and Oxytocin in Pregnant Human Myometrium with and without Oxytocin Pretreatment. Anesthesiology. 2016;124(2):378-86.

Malm M, Madsen I, Kjellstrom J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. J Pept Sci. 2018;24(6):e3082.

van Dongen PW, de Groot AN. History of ergot alkaloids from ergotism to ergometrine. Eur J Obstet Gynecol Reprod Biol. 1995;60(2):109-16.

McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev. 2004(1):CD000201.

Taylor GJ, Cohen B. Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol. 1985;66(6):821-2.

Soltan AS, Read MD. Postpartum eclampsia associated with ergometrine maleate administration. Br J Obstet Gynaecol. 1994;101(10):926-7.

Salati JA, Leathersich SJ, Williams MJ, Cuthbert A, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. 2019;4:CD001808.

Challis JR, Lye SJ, Gibb W. Prostaglandins and parturition. Ann N Y Acad Sci. 1997;828:254-67.

Palliser HK, Hirst JJ, Ooi GT, Rice GE, Dellios NL, Escalona RM, et al. Prostaglandin e and f receptor expression and myometrial sensitivity at labor onset in the sheep. Biol Reprod. 2005;72(4):937-43.

Balki M, Kanwal N, Erik-Soussi M, Kingdom J, Carvalho JC. Contractile efficacy of various prostaglandins in pregnant rat myometrium pretreated with oxytocin. Reprod Sci. 2012;19(9):968-75.

Balki M, Erik-Soussi M, Ramachandran N, Kingdom J, Carvalho JC. The Contractile Effects of Oxytocin, Ergonovine, and Carboprost and Their Combinations: an In Vitro Study on Human Myometrial Strips. Anesth Analg. 2015;120(5):1074-84.

Douglas MJ, Farquharson DF, Ross PL, Renwick JE. Cardiovascular collapse following an overdose of prostaglandin F2 alpha: a case report. Can J Anaesth. 1989;36(4):466-9.

Kilpatrick AW, Thorburn J. Severe hypotension due to intramyometrial injection of prostaglandin E2. Anaesthesia. 1990;45(10):848-9.

Jelinek J, Roztocil A, Pilka L. [Treatment of post-partum atonic hemorrhage with prostaglandin F2 alpha analogs]. Ceska Gynekol. 1995;60(6):290-2.

Kupferminc MJ, Gull I, Bar-Am A, Daniel Y, Jaffa A, Shenhav M, et al. Intrauterine irrigation with prostaglandin F2-alpha for management of severe postpartum hemorrhage. Acta Obstet Gynecol Scand. 1998;77(5):548-50. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017989s019lbl.pdf.

Lalonde A, International Federation of G, Obstetrics. Prevention and treatment of postpartum hemorrhage in low-resource settings. Int J Gynaecol Obstet. 2012;117(2):108-18.

Tuncalp O, Hofmeyr GJ, Gulmezoglu AM. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012(8):CD000494.

Hofmeyr GJ, Walraven G, Gulmezoglu AM, Maholwana B, Alfirevic Z, Villar J. Misoprostol to treat postpartum haemorrhage: a systematic review. BJOG. 2005;112(5):547-53.

Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014;15(3):421-8.

Kielbasa LA, Daniel KL. Topical alprostadil treatment of female sexual arousal disorder. Ann Pharmacother. 2006;40(7-8):1369-76.[Available from: https://www.codifa.it/farmaci/n/nalador-sulprostone-prostaglandine.

Schmitz T, Tararbit K, Dupont C, Rudigoz RC, Bouvier-Colle MH, Deneux-Tharaux C, et al. Prostaglandin E2 analogue sulprostone for treatment of atonic postpartum hemorrhage. Obstet Gynecol. 2011;118(2 Pt 1):257-65.

Goffinet F, Haddad B, Carbonne B, Sebban E, Papiernik E, Cabrol D. [Practical use of sulprostone in the treatment of hemorrhages during delivery]. J Gynecol Obstet Biol Reprod (Paris). 1995;24(2):209-16.

Phuapradit W, Saropala N, Rangsipragarn R. Treatment of atonic postpartum hemorrhage with a prostaglandin E2 analogue. J Med Assoc Thai. 1993;76(6):303-7.

Vavala V, Torello-Viera M, Brustia R, Giana M, Monaco A, Scribanti A. [Sulprostone in the prevention and therapy of hemorrhage due to postpartal uterine atony]. Minerva Med. 1990;81(3 Suppl):105-6.

SNLG. Emorragia post partum: come prevenirla, come curarla. 2016.

Daykan Y, Biron-Shental T, Navve D, Miller N, Bustan M, Sukenik-Halevy R. Prediction of the efficacy of dinoprostone slow release vaginal insert (Propess) for cervical ripening: A prospective cohort study. J Obstet Gynaecol Res. 2018;44(9):1739-46.

Vollebregt A, van't Hof DB, Exalto N. Prepidil compared to Propess for cervical ripening. Eur J Obstet Gynecol Reprod Biol. 2002;104(2):116-9.